These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 33326421)
1. Estimating the herd immunity threshold by accounting for the hidden asymptomatics using a COVID-19 specific model. Kaushal S; Rajput AS; Bhattacharya S; Vidyasagar M; Kumar A; Prakash MK; Ansumali S PLoS One; 2020; 15(12):e0242132. PubMed ID: 33326421 [TBL] [Abstract][Full Text] [Related]
2. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021. Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873 [TBL] [Abstract][Full Text] [Related]
3. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]. Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F; Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811 [TBL] [Abstract][Full Text] [Related]
4. Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects. Bicher M; Rippinger C; Schneckenreither G; Weibrecht N; Urach C; Zechmeister M; Brunmeir D; Huf W; Popper N Sci Rep; 2022 Feb; 12(1):2872. PubMed ID: 35190590 [TBL] [Abstract][Full Text] [Related]
5. Dynamical Evolution of COVID-19 in Italy With an Evaluation of the Size of the Asymptomatic Infective Population. Giamberardino PD; Iacoviello D; Papa F; Sinisgalli C IEEE J Biomed Health Inform; 2021 Apr; 25(4):1326-1332. PubMed ID: 32750959 [TBL] [Abstract][Full Text] [Related]
6. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses. Yang Y; Wang X; Du RH; Zhang W; Si HR; Zhu Y; Shen XR; Li Q; Li B; Men D; Zhou YN; Wang H; Tong XL; Zhang XE; Shi ZL; Zhou P Emerg Microbes Infect; 2021 Dec; 10(1):905-912. PubMed ID: 33870851 [TBL] [Abstract][Full Text] [Related]
8. Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment. Norsa L; Cosimo P; Indriolo A; Sansotta N; D'Antiga L; Callegaro A Gastroenterology; 2020 Dec; 159(6):2229-2231.e2. PubMed ID: 32860790 [No Abstract] [Full Text] [Related]
9. How to Understand Herd Immunity in the Context of COVID-19. Dong M; He F; Deng Y Viral Immunol; 2021 Apr; 34(3):174-181. PubMed ID: 33351708 [TBL] [Abstract][Full Text] [Related]
10. Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity. Wu J; Liang BY; Fang YH; Wang H; Yang XL; Shen S; Chen LK; Li SM; Lu SH; Xiang TD; Liu J; Le-Trilling VTK; Lu MJ; Yang DL; Deng F; Dittmer U; Trilling M; Zheng X Front Immunol; 2021; 12():722027. PubMed ID: 34489971 [TBL] [Abstract][Full Text] [Related]
11. The impact of invisible-spreaders on COVID-19 transmission and work resumption. Wu C; Xu C; Mao F; Xu X; Zhang C PLoS One; 2022; 17(1):e0252994. PubMed ID: 35020722 [TBL] [Abstract][Full Text] [Related]
12. The long road. Cohen J Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838 [No Abstract] [Full Text] [Related]
14. Achieving herd immunity against COVID-19 at the country level by the exit strategy of a phased lift of control. de Vlas SJ; Coffeng LE Sci Rep; 2021 Feb; 11(1):4445. PubMed ID: 33627674 [TBL] [Abstract][Full Text] [Related]
15. Estimating the effects of asymptomatic and imported patients on COVID-19 epidemic using mathematical modeling. Sun T; Weng D J Med Virol; 2020 Oct; 92(10):1995-2003. PubMed ID: 32330299 [TBL] [Abstract][Full Text] [Related]
16. What the data say about asymptomatic COVID infections. Nogrady B Nature; 2020 Nov; 587(7835):534-535. PubMed ID: 33214725 [No Abstract] [Full Text] [Related]
17. A Recursive Model of the Spread of COVID-19: Modelling Study. Ilyin SO JMIR Public Health Surveill; 2021 Apr; 7(4):e21468. PubMed ID: 33871381 [TBL] [Abstract][Full Text] [Related]
18. Trends in adaptation of fifteen European countries population to SARS-CoV-2 in March-May 2020: Can Taiwanese experience be adopted? Sharov KS J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):679-687. PubMed ID: 32798031 [TBL] [Abstract][Full Text] [Related]
19. Challenges in Engendering Herd Immunity to SARS-CoV-2 Infection: Possibly Impossible But Plausibile. Mukherjee S; Ray SK Infect Disord Drug Targets; 2022; 22(4):e170122200309. PubMed ID: 35040409 [TBL] [Abstract][Full Text] [Related]
20. [Analysis of application of herd immunity as a control strategy for COVID-19]. Wu ZY Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Jul; 41(7):986-989. PubMed ID: 32397700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]